WO2012069474A3 - A method for reducing potential virus burden in a sample by cyanate treatment - Google Patents

A method for reducing potential virus burden in a sample by cyanate treatment Download PDF

Info

Publication number
WO2012069474A3
WO2012069474A3 PCT/EP2011/070683 EP2011070683W WO2012069474A3 WO 2012069474 A3 WO2012069474 A3 WO 2012069474A3 EP 2011070683 W EP2011070683 W EP 2011070683W WO 2012069474 A3 WO2012069474 A3 WO 2012069474A3
Authority
WO
WIPO (PCT)
Prior art keywords
sample
reducing potential
potential virus
virus burden
cyanate
Prior art date
Application number
PCT/EP2011/070683
Other languages
French (fr)
Other versions
WO2012069474A2 (en
Inventor
Lars Foldager
Søren CHRISTENSEN
Allan William Hey
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of WO2012069474A2 publication Critical patent/WO2012069474A2/en
Publication of WO2012069474A3 publication Critical patent/WO2012069474A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a method for reducing viral contamination in a sample comprising the step of adding cyanate to said sample as well as a method for carbamylating erythropoietin obtained from a crude harvest by using this virus reducing step.
PCT/EP2011/070683 2010-11-24 2011-11-22 A method for reducing potential virus burden in a sample by cyanate treatment WO2012069474A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41685010P 2010-11-24 2010-11-24
US61/416,850 2010-11-24
DKPA201001067 2010-11-24
DKPA201001067 2010-11-24

Publications (2)

Publication Number Publication Date
WO2012069474A2 WO2012069474A2 (en) 2012-05-31
WO2012069474A3 true WO2012069474A3 (en) 2012-07-26

Family

ID=45033971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/070683 WO2012069474A2 (en) 2010-11-24 2011-11-22 A method for reducing potential virus burden in a sample by cyanate treatment

Country Status (1)

Country Link
WO (1) WO2012069474A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015613A1 (en) * 1989-06-15 1990-12-27 Rorer International (Overseas) Inc. Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
WO2003045996A1 (en) * 2001-11-28 2003-06-05 Sandoz Gmbh Chromatographic purification of recombinant human erythropoietin
WO2006002646A2 (en) * 2004-07-07 2006-01-12 H. Lundbeck A/S Novel carbamylated epo and method for its production
WO2006050819A1 (en) * 2004-11-09 2006-05-18 Medizinische Universität Wien Pharmaceutical preparation for the treatment of friedreich’s ataxia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US20040091961A1 (en) 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
KR20180123731A (en) 2008-01-22 2018-11-19 아라임 파마슈티칼즈, 인크. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015613A1 (en) * 1989-06-15 1990-12-27 Rorer International (Overseas) Inc. Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
WO2003045996A1 (en) * 2001-11-28 2003-06-05 Sandoz Gmbh Chromatographic purification of recombinant human erythropoietin
WO2006002646A2 (en) * 2004-07-07 2006-01-12 H. Lundbeck A/S Novel carbamylated epo and method for its production
WO2006050819A1 (en) * 2004-11-09 2006-05-18 Medizinische Universität Wien Pharmaceutical preparation for the treatment of friedreich’s ataxia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALLAN DARLING: "Validation of Biopharmaceutical Purification Processes for Virus Clearance Evaluation", MOLECULAR BIOTECHNOLOGY, vol. 21, no. 1, 1 May 2002 (2002-05-01), pages 057 - 084, XP055022503, ISSN: 1073-6085, DOI: 10.1385/MB:21:1:057 *
ROBERTS ET AL: "Virus inactivation by protein denaturants used in affinity chromatography", BIOLOGICALS, ACADEMIC PRESS LTD., LONDON, GB, vol. 35, no. 4, 1 October 2007 (2007-10-01), pages 343 - 347, XP022300727, ISSN: 1045-1056, DOI: 10.1016/J.BIOLOGICALS.2007.02.005 *

Also Published As

Publication number Publication date
WO2012069474A2 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
WO2011119004A3 (en) Method of producing d-psicose crystals
UY34217A (en) ? METHOD OF CONTROL OF INSECTS AND MALEZAS, SEQUENCE OF DNA, PLANT AND SEED OF SOYA AND COMPOSITION DERIVED FROM THESE
EP2655795A4 (en) Multi-stage fracture injection process for enhanced resource production from shales
WO2012131555A3 (en) Hetero-dimeric immunoglobulins
EP2649178B8 (en) Mgmt-based method for obtaining high yield of recombinant protein expression
WO2011119777A3 (en) Compositions and methods for treatment of neurodegenerative disease
WO2013109974A3 (en) Anti-cxcr3 antibodies
WO2013034979A3 (en) Crystalline forms of cabazitaxel
WO2013121436A3 (en) A process for preparation of rivaroxaban and intermediates thereof
PL2545019T3 (en) Method for distillative extraction of pure 1,3-butadiene from raw 1,3-butadiene
WO2013080217A3 (en) Crystalline forms of carbazitaxel and process for preparation thereof
WO2011163566A3 (en) Methods of treating patients with immune-related diseases
WO2014057498A3 (en) Process for the preparation of cobicistat intermediates
MX347587B (en) Asymmetric ureas and medical uses thereof.
WO2012112674A3 (en) Compounds and methods of use thereof for treating neurodegenerative disorders
EP2669382A4 (en) Cellulosic biomass treatment method, method of producing sugar, alcohol or organic acid from cellulosic biomass
IN2015KN00492A (en)
ZA201205914B (en) Method of improving plant yield of soybeans by treatment with herbicides
WO2013022550A3 (en) Small molecule inhibitors of ebola and lassa fever viruses
WO2012037116A3 (en) Genetic variations associated with common variable immunodeficiency (cvid) and methods of use thereof
WO2010098583A3 (en) Novel method for preparing statin compounds or salts thereof, and intermediate compounds used in same
BR112014010278A2 (en) method of eradicating undesirable species from a treatment zone, fumigant composition, and method of making a fumigant composition
WO2012154271A3 (en) Method and cells for identifying rig-i pathway regulators
WO2013072933A3 (en) Process for preparation of 2-acetamido-n-benzyl-3-methoxypropionamide
WO2013024267A3 (en) Stabilized compositions against ionising radiation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11787855

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11787855

Country of ref document: EP

Kind code of ref document: A2